185 related articles for article (PubMed ID: 37193673)
21. RSV disease in infants and young children: Can we see a brighter future?
Baraldi E; Checcucci Lisi G; Costantino C; Heinrichs JH; Manzoni P; Riccò M; Roberts M; Vassilouthis N
Hum Vaccin Immunother; 2022 Nov; 18(4):2079322. PubMed ID: 35724340
[TBL] [Abstract][Full Text] [Related]
22. Prevention strategies for respiratory syncytial virus: passive and active immunization.
Englund JA
J Pediatr; 1999 Aug; 135(2 Pt 2):38-44. PubMed ID: 10431138
[TBL] [Abstract][Full Text] [Related]
23. Respiratory syncytial virus immunoglobulin and monoclonal antibodies in the prevention and treatment of respiratory syncytial virus infection.
Welliver RC
Semin Perinatol; 1998 Feb; 22(1):87-95. PubMed ID: 9523402
[TBL] [Abstract][Full Text] [Related]
24. The Path Towards Effective Respiratory Syncytial Virus Immunization Policies: Recommended Actions.
Martinón-Torres F; Navarro-Alonso JA; Garcés-Sánchez M; Soriano-Arandes A
Arch Bronconeumol; 2023 Sep; 59(9):581-588. PubMed ID: 37414639
[TBL] [Abstract][Full Text] [Related]
25. The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.
Baral R; Li X; Willem L; Antillon M; Vilajeliu A; Jit M; Beutels P; Pecenka C
Vaccine; 2020 Jul; 38(33):5139-5147. PubMed ID: 32586761
[TBL] [Abstract][Full Text] [Related]
26. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
Resch B
Hum Vaccin Immunother; 2017 Sep; 13(9):2138-2149. PubMed ID: 28605249
[TBL] [Abstract][Full Text] [Related]
27. An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children.
Nair H; Verma VR; Theodoratou E; Zgaga L; Huda T; Simões EA; Wright PF; Rudan I; Campbell H
BMC Public Health; 2011 Apr; 11 Suppl 3(Suppl 3):S30. PubMed ID: 21501449
[TBL] [Abstract][Full Text] [Related]
28. New strategies for the prevention of respiratory syncytial virus (RSV).
Messina A; Germano C; Avellis V; Tavella E; Dodaro V; Massaro A; Vitale R; Masturzo B; Manzoni P
Early Hum Dev; 2022 Nov; 174():105666. PubMed ID: 36174288
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions.
Laufer RS; Driscoll AJ; Baral R; Buchwald AG; Campbell JD; Coulibaly F; Diallo F; Doumbia M; Galvani AP; Haidara FC; Kotloff KL; Keita AM; Neuzil KM; Orenstein EW; Orenstein LAV; Pecenka C; Sow S; Tapia MD; Ortiz JR; Fitzpatrick MC
Vaccine; 2021 Aug; 39(35):5037-5045. PubMed ID: 34325934
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of pharmaceutical strategies to prevent respiratory syncytial virus disease in young children: a decision-support model for use in low-income and middle-income countries.
Mahmud S; Baral R; Sanderson C; Pecenka C; Jit M; Li Y; Clark A
BMC Med; 2023 Apr; 21(1):138. PubMed ID: 37038127
[TBL] [Abstract][Full Text] [Related]
31. Current respiratory syncytial virus prevention strategies in high-risk infants.
Weisman LE
Pediatr Int; 2002 Oct; 44(5):475-80. PubMed ID: 12225544
[TBL] [Abstract][Full Text] [Related]
32. Respiratory syncytial virus infection and the need for immunization in Korea.
Kim HY; Yun KW; Cheong HJ; Choi EH; Lee HJ
Expert Rev Vaccines; 2023; 22(1):327-340. PubMed ID: 36960592
[TBL] [Abstract][Full Text] [Related]
33. Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal.
Chu HY; Tielsch J; Katz J; Magaret AS; Khatry S; LeClerq SC; Shrestha L; Kuypers J; Steinhoff MC; Englund JA
J Clin Virol; 2017 Oct; 95():90-95. PubMed ID: 28903080
[TBL] [Abstract][Full Text] [Related]
34. Passive protection against respiratory syncytial virus disease in infants: the role of maternal antibody.
Englund JA
Pediatr Infect Dis J; 1994 May; 13(5):449-53. PubMed ID: 8072835
[TBL] [Abstract][Full Text] [Related]
35. Summary of the Vaccines and Related Biological Products Advisory Committee meeting held to consider evaluation of vaccine candidates for the prevention of respiratory syncytial virus disease in RSV-naïve infants.
Browne SK; Beeler JA; Roberts JN
Vaccine; 2020 Jan; 38(2):101-106. PubMed ID: 31706809
[TBL] [Abstract][Full Text] [Related]
36. Passive IgA monoclonal antibody is no more effective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus.
Fisher RG; Crowe JE; Johnson TR; Tang YW; Graham BS
J Infect Dis; 1999 Oct; 180(4):1324-7. PubMed ID: 10479165
[TBL] [Abstract][Full Text] [Related]
37. Treatment and prevention options for respiratory syncytial virus infections.
Levin MJ
J Pediatr; 1994 May; 124(5 Pt 2):S22-7. PubMed ID: 8169754
[TBL] [Abstract][Full Text] [Related]
38. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
Groothuis JR; Hoopes JM; Hemming VG
Adv Ther; 2011 Feb; 28(2):110-25. PubMed ID: 21318605
[TBL] [Abstract][Full Text] [Related]
39. Immunoglobulin for preventing respiratory syncytial virus infection.
Wang EE; Tang NK
Cochrane Database Syst Rev; 2000; (2):CD001725. PubMed ID: 10796658
[TBL] [Abstract][Full Text] [Related]
40. Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus.
Hervé PL; Dhelft V; Zuniga A; Ghasparian A; Rassek O; Yim KC; Donne N; Lambert PH; Benhamou PH; Sampson HA; Mondoulet L
Vaccine; 2021 Jul; 39(32):4555-4563. PubMed ID: 34154864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
